Bullish
Johnson & Johnson's RYBREVANT FASPRO™ shows 56% response rate in head and neck cancer trial
Johnson & Johnson's investigational treatment, RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), demonstrated a 56% overall response rate in a Phase 1b/2 study for first-line recurrent or metastatic head and neck squamous cell carcinoma. This promising result suggests potential for improved outcomes in this patient population.
Key points
- RYBREVANT FASPRO™ achieves 56% overall response rate in head and neck cancer trial.
Sources
AI-generated from public news sources. Not financial advice.
